Merck and Co., Inc. (MRK) |
130.72 3.72 (2.93%) 04-25 16:02 |
Open: | 129.69 |
High: | 132.8 |
Low: | 128.76 |
Volume: | 12,739,818 |
Market Cap: | 331,067(M) |
PE Ratio: | 933.71 |
Exchange: | New York Stock Exchange |
Industry: | Drug Manufacturers - General |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 155.46 |
Resistance 1: | 133.10 |
Pivot price: | 126.60 |
Support 1: | 126.90 |
Support 2: | 123.06 |
52w High: | 133.1 |
52w Low: | 99.14 |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
EPS | 0.140 |
Book Value | 14.850 |
PEG Ratio | 0.22 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.61 |
Operating Margin (%) | 0.08 |
Return on Assets (ttm) | 2.6 |
Return on Equity (ttm) | 0.9 |
Thu, 25 Apr 2024
Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook - Yahoo Finance
Thu, 25 Apr 2024
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales - Yahoo Finance
Thu, 25 Apr 2024
MRK Earnings: Merck Q1 2024 profit jumps on 9% revenue growth - AlphaStreet
Thu, 25 Apr 2024
Merck stock gains on Q1 2024 beat (NYSE:MRK) - Seeking Alpha
Thu, 25 Apr 2024
Merck in charts: Pharmaceutical segment soars on KEYTRUDA, GARDASIL strength in Q1 - Seeking Alpha
Thu, 25 Apr 2024
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales - CNBC
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |